Search Press releases Keywords From To 1 Feb 2022 UCB Commences Tender Offer to Acquire Zogenix, Inc. Read More 28 Jan 2022 Disposals of own shares Read More 24 Jan 2022 BIMZELX[®] (bimekizumab) Approved in Japan for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Psoriatic Erythroderma Read More 21 Jan 2022 Disposals of own shares Read More 21 Jan 2022 Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Second Phase 3 Psoriatic Arthritis Study Read More 19 Jan 2022 UCB to acquire Zogenix Read More Pagination First page Previous page Previous … Page 25 Page 26 Page 27 Page 28 Current page 29 Page 30 Page 31 Page 32 Page 33 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe